Insight Molecular Diagnostics

Historical price data

iMDx is a U.S.-based public company advancing precision medicine through innovative, blood-based molecular diagnostics in transplantation and oncology. Its strategic rebrand from Oncocyte solidified a focus on commercializing and developing tests for transplant rejection monitoring and cancer therapy guidance. The company's core strategy involves leveraging its proprietary cfDNA analysis platform to decentralize testing, making critical diagnostics more accessible to healthcare systems and patients. Key achievements include the commercial launch of a transplant monitoring test and the assembly of a seasoned leadership team with deep diagnostics and commercialization expertise.

Proprietary blood-based cell-free DNA (cfDNA) analysis platform focusing on donor-derived cfDNA (dd-cfDNA) for transplant rejection monitoring and circulating tumor DNA (ctDNA) with genomic copy number and gene expression analysis for oncology applications.

In transplant monitoring, iMDx competes directly with established leaders like Natera and CareDx. In oncology, it faces a crowded field including Guardant Health and Foundation Medicine in liquid biopsy, and NanoString in tumor microenvironment analysis, requiring clear differentiation and proof of clinical utility.